Mergers and Acquisitions - Cixing Co., Ltd. plans to acquire 75% of Shenyang Shunyi Technology Co., Ltd. through a combination of issuing shares and cash payments, while also raising supporting funds from no more than 35 qualified investors [1] - United Optoelectronics intends to purchase 100% of Changyi Optoelectronics from 12 shareholders via share issuance and will also raise supporting funds [2] - Inte Group's subsidiary, Inte Pharmaceutical, successfully acquired 100% equity of Zhejiang Huadong Pharmaceutical Group Co., Ltd. for 369 million yuan and signed a transaction contract with the transferor [3] Shareholding Changes - Guokang Biochemical announced that shareholders plan to collectively reduce their holdings by no more than 6% of the company's total shares, with specific plans from two major shareholders to reduce by 3% each [4] - Ruilian New Materials reported that a major shareholder, Guofu Yongyu, plans to reduce its holdings by up to 3.33%, equivalent to 573,110 shares [5] - Hongxin Technology disclosed that two major shareholders, Baiqiang and Taizhou Qixin, plan to reduce their holdings by 2.62% and 2.12% respectively [6] Risk Matters - Sinovac Biotech highlighted the high-tech, high-risk, and high-value characteristics of its innovative drugs, emphasizing the uncertainties involved in the research and approval processes [7] - Zhongheng Design noted that the revenue from its low-altitude economy and commercial aerospace projects is minimal compared to its consolidated financial statements, despite winning several contracts in these sectors [8] Restructuring - *ST Xinyan announced that it received a notice from a creditor applying for the company's restructuring and pre-restructuring procedures [10]

Group 1 - The EU plans to restrict Chinese companies' participation in public procurement for medical devices, which China opposes as it harms the interests of Chinese enterprises and creates new trade barriers [1] - The Ministry of Commerce and five other departments are organizing the 2025 New Energy Vehicle rural outreach initiative, aiming to enhance charging infrastructure and promote high-quality resources in rural areas [1] - Regulatory authorities are increasing focus on "small essays" related to the capital market, with local securities regulatory bureaus collecting leads and suggestions to address issues caused by "black mouths" in the capital market [1] Group 2 - Diou Home's controlling shareholder and actual controller are planning changes in concerted actions, leading to a stock suspension [2] - Innovent Biologics has multiple innovative drug projects still in the preclinical stage [2] - Cuitui Medical's "youthful needle" has received NMPA registration approval [2] - The retail and order business revenue of Cuiwei Co. has seen a significant decline [2] - Debang Co. has not yet applied unmanned logistics vehicles in practice [2] - Baili Electric's nuclear fusion-related business revenue is minimal and will not significantly impact performance [2] - Shuotai Shen's conditional listing application for STSP-0601 has been accepted by the National Medical Products Administration [2]

Group 1: Economic Outlook - OECD forecasts global economic growth at 2.9% for both 2025 and 2026, a downward revision of 0.2 and 0.1 percentage points from March 2023 predictions [2] Group 2: Industry Developments - The Ministry of Industry and Information Technology announced the launch of the 2025 New Energy Vehicles Going to the Countryside initiative, promoting reliable and high-quality new energy models in rural areas [3] - From January to April, China's electronic information manufacturing industry saw a year-on-year increase of 11.3% in added value, outperforming overall industrial and high-tech manufacturing growth by 4.9 and 1.5 percentage points respectively [3] Group 3: Company News - Baoli Electric's revenue from nuclear fusion-related business is currently minimal, accounting for less than 1% of total revenue in 2024 [5] - Zhongheng Design's revenue from "low-altitude economy" and "commercial aerospace" projects is also a small proportion of consolidated revenue [5] - Saily's May sales of new energy vehicles reached 39,982 units, a year-on-year increase of 17.15% [6] - Deli Co. plans to invest approximately 300 million yuan in new lithium battery pilot and industrialization projects [7] - Lepu Medical's polylactic acid facial filler has received NMPA registration approval [7]

Group 1 - Baili Electric's revenue from controlled nuclear fusion business is small and will not significantly impact its performance [1] - Debang has not yet applied autonomous logistics vehicles in practice, and the related concept will not affect its performance [2] - Cuiwei's retail and acquiring business revenues have decreased significantly, and the company is currently in a loss state [3] Group 2 - Seres reported a 19.46% year-on-year increase in cumulative sales of the Wanjie M9 from January to May [4] - Sinovac's multiple innovative drug projects are still in the pre-clinical stage, with high uncertainty regarding future developments [5] - Citic Bank has been approved to establish a financial asset investment company with a registered capital of RMB 10 billion [6] Group 3 - Four-dimensional Map signed a strategic cooperation framework agreement with Alibaba Cloud to explore collaboration in various fields [7] - Longi Green Energy's HPBC2.0 product orders have significantly increased, with over 50% coming from overseas customers [8] - Shutai Shen's application for conditional marketing approval of STSP-0601 has been accepted by the National Medical Products Administration [9] Group 4 - Gongchuang Lawn's products are primarily for export, and there is significant uncertainty regarding U.S. tariff policies [10] - Zhongheng Design's income from low-altitude economy and commercial aerospace projects is currently very small [11] - Wanrun's chairman Huang Yiwu has resigned due to work adjustments [12] Group 5 - Guokai Military Industry's shareholder plans to reduce holdings by no more than 2.97% [13] - Guangkang Biochemical's shareholders plan to reduce holdings by no more than 6% [13] - Far East Holdings' shareholder plans to reduce holdings by no more than 2.30% [13] - Industrial Fulian has repurchased 7.6974 million shares, using a total of RMB 147 million [13]

证券代码：688136 证券简称：科兴制药 公告编号：2025-030 科兴生物制药股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 科兴生物制药股份有限公司（以下简称"公司"）股票连续三个交易日 内（2025 年 5 月 29 日、5 月 30 日、6 月 3 日）收盘价格涨幅偏离值累计超过 30%， 属于股票交易异常波动。 经公司自查，并向公司控股股东、实际控制人进行书面询证，截至本公 告披露日，确认不存在关于公司的应披露而未披露的重大事项，公司日常经营情 况正常，未发生重大变化，所处的行业政策未发生重大调整。 二、公司关注并核实的相关情况 根据上海证券交易所相关规定，公司对相关问题进行了必要核实。现说明如 下： （一）生产经营情况 经自查，公司目前日常经营情况正常，未发生重大变化，所处的行业政策未 发生重大调整。 （二）重大事项情况 经公司自查，并向公司控股股东、实际控制人进行书面询证，截至目前，不 存在影响上市公司股票交易异常波动的重大事项，不存在其他应披露而未披露的 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/3/19 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 3 月 3 | 17 | 日~2026 | 年 | 月 | 16 日 | | 预计回购金额 | 3,000万元~6,000万元 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | □用于转换公司可转债 □为维护公司价值及股东权益 | | | | | | | 累计已回购股数 | 530,353股 | | | | | | | 累计已回购股数占总股本比例 | 0.27% | | | | | | | 累计已回购金额 | 1,735.06万元 | | | | | | | 实际回购价格区间 | 23.14元/股~35.45元/股 | | | | | | 一、回购股份的基本情况 科兴生物制药股份有限公司（以下简称" ...

特此回函! 关于《科兴生物制药股份有限公司股票交易异常波动询证函》的回函 科兴生物制药股份有限公司: 贵公司发出的《科兴生物制药股份有限公司股票交易异常波动询证函》已收 悉,经过认真自查,现就有关情况回复如下: 截至本函签署日,本人作为贵公司的实际控制人,不存在影响贵公司股票交 易异常波动的重大事项,不存在其他应披露而未披露的重大信息,包括但不限于 筹划并购重组、股份发行、债务重组、业务重组、资产剥离和资产注入等对贵公 司股票交易价格产生较大影响的重大事项。本人在贵公司本次股票交易异常波动 期间未买卖贵公司股票。 实际控制人: 2025年6月3日 ...

关于《科兴生物制药股份有限公司股票交易异常波动询证函》的回函 二、截至目前,本企业不存在处于筹划阶段的涉及贵公司的重大事项,包括 但不限于重大资产重组、股份发行、上市公司收购、债务重组、业务重组、资产 剥离、资产注入等重大事项; 三、在本次股票交易异常波动期间,本企业不存在买卖贵公司股票的情形。 特此回函! 深圳科洁 科兴生物制药股份有限公司: 贵公司发出的《科兴生物制药股份有限公司股票交易异常波动询证函》已收 悉,经过认真自查,现就有关情况回复如下: 一、截至目前,本企业不存在除在指定媒体上已公开披露的信息以外影响贵 公司股票交易价格异常波动的重大事宜; ...

Market Overview - A-shares experienced a strong upward trend, with significant gains in the pharmaceutical and financial sectors, while Hong Kong stocks also rose, with the Hang Seng Index and Hang Seng Tech Index both increasing by over 1% [1] - The Shanghai Composite Index closed up 0.43% at 3361.98 points, the Shenzhen Component Index rose 0.16% to 10057.17 points, and the ChiNext Index increased by 0.48% to 2002.7 points [1] Pharmaceutical Sector - The pharmaceutical sector saw a notable surge, particularly in innovative and weight-loss drug stocks, with Shuyou Shen (300204) hitting the daily limit and accumulating a nearly 190% increase over the past 10 trading days [3][4] - Other pharmaceutical stocks such as Huana Pharmaceutical and Kexing Pharmaceutical also reached new highs, with Kexing rising approximately 15% [3] - The National Medical Products Administration recently approved 11 new innovative drugs, which is expected to boost the performance of related companies [6] Medical Aesthetics Sector - The medical aesthetics sector also showed strong performance, with stocks like Guanhao Biological (300238) and Shuiyang Co. (300740) hitting the daily limit, and other companies like Langzi Co. and Jiuzhitang also experiencing significant gains [5] Gold Sector - The gold sector saw a notable rise, with stocks such as Mankalon (300945), Western Gold (601069), and Caibai Co. (605599) hitting the daily limit, while Chifeng Gold (600988) increased by over 4% [7][8] - COMEX gold futures rose by 2.74% to $3406.4 per ounce, marking a return above the $3400 level for the first time since May 8 [8][9] Digital Currency Sector - The digital currency sector was active, with stocks like Sifang Precision (300468) rising over 10%, and companies like Cuiwei Co. (603123) and Hengbao Co. (002104) hitting the daily limit [10][11] - The Hong Kong government recently enacted the "Stablecoin Ordinance," which aims to promote financial innovation while maintaining stability, marking a significant step in the digital asset field [11][12]

场内近3400股飘红，创新药、减肥药等医药股集体爆发，舒泰神再度涨停，近10日累计大涨近190%；华纳药厂、科兴制药等创出新高；医美概念拉升，朗姿股份、 九芝堂、哈三联等涨停，华熙生物涨约7%；银行股延续强势，中信银行、浦发银行等创出新高；黄金概念活跃，曼卡龙、西部黄金、菜百股份等涨停；体育概念崛 起，金陵体育、创源股份涨停；数字货币概念活跃，翠微股份、恒宝股份涨停斩获3连板，御银股份连续4日涨停。 港股方面，老铺黄金盘中涨近8%逼近1000港元大关，续创历史新高；此外，微创脑科学涨约20%，理想汽车涨近6%，长和、比亚迪股份涨约4%；连连数字大跌超 39%。 医药板块爆发 创新药、减肥药概念股强势拉升，截至收盘，舒泰神、华纳药厂、北陆药业20%涨停，科兴制药涨约15%创出新高。值得注意的是，舒泰神近10个交易日已累计大 涨近190%。 3日，A股震荡上扬，医药、金融等板块强势；港股亦走强，恒生指数、恒生科技指数均涨超1%。 具体来看，两市股指盘中维持震荡上扬走势，北证50指数涨超1%。截至收盘，沪指涨0.43%报3361.98点，深证成指涨0.16%报10057.17点，创业板指涨0.48%报 2002.7 ...